Method: 91 meningiomas were screened for activating mutations in "hot spot" exons 9, 20 of PIK3CA using Real Time PCR and High Resolution Melting Analysis. PIK3CA wild-type samples were analyzed for mutations in exon 4 of AKT1. The mutations were verified by sequencing and/or pyrosequencing Results: Mutations were detected in 2 out of 91 samples (2 %) in exon 9 of PIK3CA and were identified as p.E547K and p.S541F. Regarding exon 20, 7 out of 91 samples (7,5 %) showed the following mutations: p.R1023Q, p.T1025T, p.H1020V, p.M1043I, p.H1047R (2 cases), p.H1046T. Finally, in exon 4 of AKT1, 8 mutant cases were detected (9 %) all identified as p.E17K. In 19 % of the patients the activation of the PI3K/AKT pathway is due to mutations in the two examined genes. Conclusion: Aberrant activation of the PI3K/AKT pathway due to PIK3CA and AKT1 mutations is commonly observed in human meningiomas and these genes could be considered as potential targets in new therapies for cancer.